The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.

Plain-language guide to PMID 18445665 (2008): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length) in 219 children.

Key Facts

PMID: 18445665
Journal: The Journal of clinical endocrinology and metabolism
Year: 2008
Study type: Randomized Controlled Trial
Authors: Audí L et al. (10 authors)
DOI: 10.1210/jc.2008-0150

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length), published as a randomized controlled trial.

Their objective was to evaluate whether the d3/fl-GHR genotypes influence insulin sensitivity in short SGA children before or after puberty onset or during GH therapy.

Why It Was Studied

However, its influence on glucose homeostasis, at baseline or under GH therapy, has not been investigated.

Who Took Part

The abstract describes 219 children taking part.

PubMed indexes the participants as children, both men and women.

Patients included 219 short SGA children [body mass index sd score (SDS) < or = 2.0]; 159 were prepubertal (group 1), and 60 had entered puberty (group 2).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The researchers conducted a 2-yr prospective, controlled, randomized trial.

Auxological, GH secretion, and glucose homeostasis evaluation was hospital based, whereas molecular analyses and data computation were centralized.

What Was Measured

PubMed files the paper under topics including Body Mass Index, Exons, Gene Deletion, Glucose, Homeostasis, Human Growth Hormone and Infant, Small for Gestational Age.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length) in 219 children.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Thymosin Beta-4 (full length) compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Thymosin Beta-4 (full length): The natural 43-amino-acid actin-binding peptide behind the TB-500 name; tested in human trials for eye, skin-wound and heart conditions.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.